Lebrikizumab

Drug Profile

Lebrikizumab

Alternative Names: Anti-IL 13; Anti-IL13-monoclonal-antibody; Anti-interleukin-13-monoclonal-antibody; MILR1444A; PRO-301444; RG-3637; RO-5490255; TNX-650

Latest Information Update: 17 Feb 2017

Price : $50

At a glance

  • Originator Tanox
  • Developer Chugai Pharmaceutical; Comprehensive Clinical Research Network; Genentech; Roche; Tanox
  • Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Asthma
  • Phase II Atopic dermatitis; Chronic obstructive pulmonary disease; Idiopathic pulmonary fibrosis
  • Discontinued Hodgkin's disease

Most Recent Events

  • 12 Jan 2017 Roche terminates the phase II VOCALS trial in Asthma due to absence of efficacy in the LAVOLTA studies in United Kingdom, Canada, France, Netherlands, Puerto Rico, Slovakia, Spain, the US, Belgium, Mexico, Australia, Czech Republic, Denmark, New Zealand, Poland, Bulgaria and Slovenia (SC) (NCT01987492)
  • 21 Jul 2016 Discontinued - Phase-II for Asthma in Mexico, Slovenia, Denmark, Czech Republic, Australia, Belgium, Spain, Netherlands, France (SC) (Roche pipeline, July 2016)
  • 21 Jul 2016 Discontinued - Phase-II for Asthma (Adjunctive treatment, Treatment-resistant) in Sweden (SC) (Roche pipeline, July 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top